Tourmaline Bio, Inc.
TRML
$15.10
-$0.64-4.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.53% | 3.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.65% | 5.60% | |||
| Operating Income | -1.65% | -5.60% | |||
| Income Before Tax | -3.31% | -10.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.31% | -10.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.31% | -10.20% | |||
| EBIT | -1.65% | -5.60% | |||
| EBITDA | -1.64% | -5.60% | |||
| EPS Basic | -3.72% | -10.08% | |||
| Normalized Basic EPS | 22.90% | -48.10% | |||
| EPS Diluted | -3.72% | -10.08% | |||
| Normalized Diluted EPS | 22.90% | -48.10% | |||
| Average Basic Shares Outstanding | -0.40% | 0.11% | |||
| Average Diluted Shares Outstanding | -0.40% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||